Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT00981708

Lenalidomide, Dexamethasone and Cyclophosphamide in Amyloidosis (AL)

A Phase I/II Trial of Lenalidomide Combined With Cyclophosphamide and Intermediate Dose Dexamethasone in Patients With Primary (AL) Systemic Amyloidosis

Sponsor: Hellenic Cooperative Oncology Group

Conditions Amyloidosis

Interventions Lenalidomide, Dexamethasone and Cyclophosphamide

Updated 6 times since 2017 Last updated: Apr 27, 2021 Started: Feb 29, 2008 Primary completion: Jan 11, 2011 Completion: Jan 11, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Amyloidosis and is currently completed. Hellenic Cooperative Oncology Group leads this study, which shows 6 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
May 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2

Status: Unknown Status → Completed
Jan 2021 — May 2021 [monthly]

Unknown Status PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE1_PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE1_PHASE2

First recorded

Feb 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hellenic Cooperative Oncology Group
University of Athens

Data source: University of Athens

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Athens, Greece